Previous close | 12.52 |
Open | 12.49 |
Bid | 12.52 x 600 |
Ask | 12.60 x 300 |
Day's range | 11.78 - 12.74 |
52-week range | 9.56 - 31.46 |
Volume | |
Avg. volume | 815,201 |
Market cap | 890.506M |
Beta (5Y monthly) | 1.83 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.26 |
Earnings date | 07 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 33.40 |
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Insight into Zentalis Pharmaceuticals' Financial Health and Future Outlook
Azenosertib clinical development plan on track with multiple data readouts in gynecological and other cancer types anticipated in the second half of 2024 and into 2025 Final results from Phase 1 study of azenosertib in combination with gemcitabine in adult and pediatric patients with relapsed or refractory osteosarcoma to be presented at the 2024 ASCO Annual Meeting Projected cash runway into mid-2026 NEW YORK and SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasda